NBP Company Profile and Key Details

NASDAQ : NBP

NovaBridge Biosciences

$3.24

-0.265-7.56%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

NovaBridge Biosciences (NBP) stock declined over -7.56%, trading at $3.24 on NASDAQ, down from the previous close of $3.51. The stock opened at $3.51, fluctuating between $3.16 and $3.51 in the recent session.

Stock Snapshot

3.505

Prev. Close

373.46M

Market Cap

3.16

Day Low

-10.12

P/E Ratio

-0.32

EPS (TTM)

N/A

Cash Flow per Share

3.51

Open

115.27M

Number of Shares

3.51

Day High

N/A

Free Float in %

N/A

Book Value

742.3K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 10, 2026	3.51	3.51	3.16	3.24	742.37K
Mar 09, 2026	3.40	3.55	3.03	3.51	1.56M
Mar 06, 2026	3.56	3.71	3.41	3.50	1.58M
Mar 03, 2026	3.32	3.47	3.19	3.20	468.66K
Mar 02, 2026	3.25	3.48	3.16	3.45	506.07K
Feb 27, 2026	3.25	3.37	3.06	3.28	900.51K
Feb 26, 2026	3.29	3.43	3.22	3.28	949.47K
Feb 25, 2026	3.28	3.39	3.03	3.28	1.16M
Feb 24, 2026	3.21	3.33	3.20	3.25	417.02K
Feb 23, 2026	3.30	3.38	3.20	3.21	441.36K
Feb 20, 2026	3.26	3.35	3.26	3.29	248.95K
Feb 19, 2026	3.22	3.34	3.20	3.32	188.4K
Feb 18, 2026	3.25	3.35	3.18	3.29	166.67K
Feb 17, 2026	3.30	3.31	3.05	3.22	310.68K
Feb 13, 2026	3.25	3.31	3.19	3.21	141.71K
Feb 12, 2026	3.39	3.39	3.21	3.24	241.54K
Feb 11, 2026	3.41	3.45	3.30	3.39	233.1K
Feb 10, 2026	3.47	3.52	3.29	3.42	511.65K
Feb 09, 2026	3.64	3.72	3.43	3.47	341.7K
Feb 06, 2026	3.47	3.74	3.45	3.70	547.03K

Contact Details

Rockville, MD 20850

United States

https://www.i-mabbiopharma.com 240 745 6330

About Company

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Stock Peers

REGN

-9.57-1.22%

Regeneron Pharmaceuticals, Inc.$772.03 ARGX

2.39+0.32%

argenx SE$742.79 UTHR

6.64+1.25%

United Therapeutics Corporation$535.81 VRTX

38.3+8.31%

Vertex Pharmaceuticals Incorporated$499.17 MDGL

-0.42-0.10%

Madrigal Pharmaceuticals, Inc.$432.78 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-1.21-0.37%

Alnylam Pharmaceuticals, Inc.$322.38 PRAX

0.9+0.29%

Praxis Precision Medicines, Inc.$309.91 KRYS

2.43+0.94%

Krystal Biotech, Inc.$261.08 ASND

0.6+0.25%

Ascendis Pharma A/S$240.52

Company Overview

NovaBridge Biosciences (NASDAQ:NBP) closed at $3.24 USD, losing -$0.26 (-7.56%) from the previous close of $3.50. The stock is currently mid-range between its 52-week high and low $0.59 and $6.79. With a market capitalization of about $373.46 million, NovaBridge Biosciences is classified as a small-cap and shows higher-than-market volatility (beta ~1.67). Key stats such as the average daily volume over the past year has been around 735.72 thousand shares, in line with its 52-week average. Headquartered in Rockville, MD, NovaBridge Biosciences operates in the Healthcare sector and the Biotechnology industry. Led by CEO Xi-Yong Fu, the company employs approximately 32 people and listed since January 17, 2020. NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States.

Technical Performance

NBP has shown mixed momentum, gaining 5.38% over the past week and -32.06% over the past quarter, though year-to-date performance is down -1.51%. Short-term trend indicators are mixed aligned (SMA20 -2.41%, SMA50 -12.4%, SMA200 -6.09%). The stock’s 14-day RSI is 41.77 (neutral), while the ATR of 0.24 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -51.69% below its high and over 451.26% above its low. Average 10-day trading volume of 971.50 thousand shares is slightly above the 3-month average of 702.27 thousand, indicating heightened recent market interest.

Valuation Metrics

NovaBridge Biosciences trades at a P/E ratio of -33.93, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.22 suggesting the stock is closer to book value. The P/FCF stands at 195.63, also above market averages.

Dividend & Fair Value

NovaBridge Biosciences last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.12. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

NovaBridge Biosciences generated EPS of -$0.71 over the past year. Five-year average earnings growth is 28.35%. Wall Street analysts project EPS growth of -26.86% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $9.00. The high target offers 177.78% upside. The low target suggests 177.78% downside. The mean target is $9.00. This offers 177.78% upside. NovaBridge Biosciences earnings surprise history is frequent misses against expectations. The quarter that ended December 25, 2025, missed forecasts by -84.17%. The prior quarter beat by -81.22%. Over the last six quarters, Apple has recorded several small beats. These include -28.27% in October 06, 2025.

Shareholding & Insider Activity

NovaBridge Biosciences has 115.29 million shares outstanding. The public float is 148.83 million shares, elevated short interest at 5.96% of float. This equals 5.48 million shares. The short ratio is 9.35 days.

Financial & Profitability Overview

Over the trailing twelve months, NovaBridge Biosciences has not generated any revenue.
On valuation metrics, NovaBridge Biosciences trades at a P/E of -33.93, P/S of 0.00 and P/B of 1.22. The current ratio is 14.47 and quick ratio is 14.47. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of 0.56.

Price Forecast & Outlook

Our AI price prediction model suggests that NovaBridge Biosciences stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.78%, with price expected at $3.33 by March 23, 2026, within a range of $3.14 to $3.53 3-Month Outlook: Projected fall of -95.99%, reaching $0.13 by June 05, 2026, with a range of $0.11 to $0.17. 1-Year Outlook: Projected loss of -90.12%, with price at $0.32 by March 09, 2027, within a range of $0.28 to $0.36.

Key Takeaways

NovaBridge Biosciences (NASDAQ:NBP) shares are flat -1.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NovaBridge Biosciences trading at a premium to the broader market with a P/E of -33.93. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.00, suggesting 177.78% upside. Our AI forecast model points to short-term strength (2.78% over two weeks), a medium-term fall (-95.99% over three months), and a longer-term loss (-90.12% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current NovaBridge Biosciences (NBP) stock price?

NovaBridge Biosciences (NASDAQ: NBP) stock price is $3.24 in the last trading session. During the trading session, NBP stock reached the peak price of $3.51 while $3.16 was the lowest point it dropped to. The percentage change in NBP stock occurred in the recent session was -7.56% while the dollar amount for the price change in NBP stock was - $0.27.

NBP's industry and sector of operation?

The NASDAQ listed NBP is part of Biotechnology industry that operates in the broader Healthcare sector. NovaBridge Biosciences designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NBP?

No Data

How NBP did perform over past 52-week?

NBP's closing price is 444.54% higher than its 52-week low of $0.60 where as its distance from 52-week high of $6.79 is -52.28%.

How many employees does NBP have?

Number of NBP employees currently stands at 32.

Link for NBP official website?

Official Website of NBP is: https://www.i-mabbiopharma.com

How do I contact NBP?

NBP could be contacted at phone 240 745 6330 and can also be accessed through its website. NBP operates from 2440 Research Boulevard, Rockville, MD 20850, United States.

How many shares of NBP are traded daily?

NBP stock volume for the day was 742.3K shares. The average number of NBP shares traded daily for last 3 months was 735.72K.

What is the market cap of NBP currently?

The market value of NBP currently stands at $373.46M with its latest stock price at $3.24 and 115.27M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	32
Beta	1.67
Sales or Revenue	N/A
5Y Sales Change%	N/A
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

NBP Company Profile and Key Details

NovaBridge Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Dividend & Fair Value

Key Takeaways

Price Forecast & Outlook

Company Overview

Valuation Metrics